128 related articles for article (PubMed ID: 26118539)
1. Intracellular Self-Assembly of Taxol Nanoparticles for Overcoming Multidrug Resistance.
Yuan Y; Wang L; Du W; Ding Z; Zhang J; Han T; An L; Zhang H; Liang G
Angew Chem Int Ed Engl; 2015 Aug; 54(33):9700-4. PubMed ID: 26118539
[TBL] [Abstract][Full Text] [Related]
2. Folate and CD44 receptors dual-targeting hydrophobized hyaluronic acid paclitaxel-loaded polymeric micelles for overcoming multidrug resistance and improving tumor distribution.
Liu Y; Sun J; Lian H; Cao W; Wang Y; He Z
J Pharm Sci; 2014 May; 103(5):1538-47. PubMed ID: 24619562
[TBL] [Abstract][Full Text] [Related]
3. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer.
Liu Y; Huang L; Liu F
Mol Pharm; 2010 Jun; 7(3):863-9. PubMed ID: 20420443
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers.
Oldham RK; Reid WK; Barnett D
Cancer Biother Radiopharm; 2000 Apr; 15(2):153-9. PubMed ID: 10803320
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms.
Yu D; Liu B; Tan M; Li J; Wang SS; Hung MC
Oncogene; 1996 Sep; 13(6):1359-65. PubMed ID: 8808711
[TBL] [Abstract][Full Text] [Related]
8. Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line.
Nakagawa M; Enokida H; Gotanda T; Tachiwada T; Imazono Y; Kubo H; Nishiyama K; Suzuki S; Inomata K; Kishiye T
Aktuelle Urol; 2003 Jul; 34(4):250-2. PubMed ID: 14566676
[TBL] [Abstract][Full Text] [Related]
9. Establishment and characterization of a paclitaxel‑resistant human esophageal carcinoma cell line.
Wang C; Guo LB; Ma JY; Li YM; Liu HM
Int J Oncol; 2013 Nov; 43(5):1607-17. PubMed ID: 24002547
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells.
Distefano M; Scambia G; Ferlini C; Gallo D; De Vincenzo R; Filippini P; Riva A; Bombardelli E; Mancuso S
Anticancer Drug Des; 1998 Jul; 13(5):489-99. PubMed ID: 9702212
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol.
Yu D; Liu B; Jing T; Sun D; Price JE; Singletary SE; Ibrahim N; Hortobagyi GN; Hung MC
Oncogene; 1998 Apr; 16(16):2087-94. PubMed ID: 9572489
[TBL] [Abstract][Full Text] [Related]
12. [Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism].
Liu Q; Liu XJ; Chen YJ; Wang J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):326-30, 357. PubMed ID: 21826992
[TBL] [Abstract][Full Text] [Related]
13. Increased intracellular cAMP renders HL-60 cells resistant to cytotoxicity of taxol.
Pae HO; Yoo JC; Jun CD; Paik SG; Choi BM; Baek KH; Kim JM; Chung HT
Immunopharmacol Immunotoxicol; 1999 May; 21(2):233-45. PubMed ID: 10319278
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
15. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
16. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y
Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
[TBL] [Abstract][Full Text] [Related]
18. Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance.
Wang Y; Dou L; He H; Zhang Y; Shen Q
Mol Pharm; 2014 Mar; 11(3):885-94. PubMed ID: 24483832
[TBL] [Abstract][Full Text] [Related]
19. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux.
Chavanpatil MD; Patil Y; Panyam J
Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
